Lung Cancer

The Food and Drug Administration approved Tepmetko for adults with metastatic non-small cell lung cancer with MET exon 14 skipping alterations.

The Food and Drug Administration will review Augtyro for potential approval in children and adults with advanced solid cancers that harbor NTRK gene fusions.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.

At a cancer support group at my church, we sit together and share our cancer stories.

Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.

Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when compared with those treated with Imfinzi or subject to observation.

The development of immune-related side effects is associated with improved overall survival among patients with metastatic non-small cell lung cancer (NSCLC) who receive immune checkpoint inhibitor therapy.

The FDA has granted Priority Review to oral ALK inhibitor Alecensa (alectinib) for patients with early-stage ALK-positive non-small cell lung cancer.

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

For patients with advanced non-small cell lung cancer and anorexia, the use of the antidepressant Remeron has been shown to increase energy consumption, as researchers look for therapies to answer an issue faced by many patients.

Results from the phase 3 INSPIRE study showed that treatment with Iruplinalkib reduced the risk of disease progression or death by 66% among patients with ALK-positive non-small cell lung cancer.

In honor of World Cancer Day, we highlighted ongoing and successful advocacy efforts in the oncology space.

After cancer and becoming an empty nester, I thought I would be lost. But now, I'm finding purpose and following my dreams.

Some treatment-related cardiovascular events, such as atrial fibrillation, may be more common in patients with non-small cell lung cancer, research shows.

The treatment combination of avutometinib and Lumakras has been granted a Fast Track designation from the FDA in some with metastatic NSCLC.

I never told my daughters what stage my lung cancer was. Was I being genuine?

Researchers claim to have determined the maximum=tolerated dose and usage of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy boost for patients with locally advanced unresectable non-small cell lung cancer, according to recently published findings.

We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.

Months after I was told I was in remission for stage 3B lung cancer, my "normal" shifted as the COVID-19 pandemic arrived.

Some with metastatic cancers receiving end-of-life-initiated immunotherapy may have a decreased risk of mortality when treated at a high-volume facility, research found.

Rates of early mortality from NSCLC decreased in states with Medicaid expansion, according to recent research.

This past holiday season made me realize that I feel a strong sense of fulfillment as a cancer survivor and caregiver.

2023 brought some disappointing cancer news to me, but 2024, I have faith in you.

Here are four things I found to be helpful as a survivor, including showing up for myself.